Antibiotics, Volume 11, Issue 2
2022 February - 163 articles
Cover Story: The incidence of urinary tract infections (UTIs) caused by extended-spectrum B-lactamase-producing Enterobacterales (ESBL-E) has increased in French hospitals, and E. coli strains are the most prevalent species among ESBL-E. This resistance is often accompanied by co-resistance to fluoroquinolones and TMP/SMX. The therapeutic choice is limited and often concerns carbapenems, which remain the gold standard for most ESBL-E infections. Oral fosfomycin-trometamol (FT) could be an alternative to carbapenems in male ESBL-E UTIs, with a high microbiological eradication rate and a simple administration, but needs to be balanced against the risk of drug interactions and adverse effects. In this current paper, we were interested in describing the clinical evolution and safety of male MDR Enterobacterales UTI cases treated with oral FT. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.